

| Número de catálogo | HB941206 |
|---|---|
| Descripción |
Anti-Human VEGFA (DRL_BZ) (HB941206) is a research-grade recombinant antibody targeting Vascular endothelial growth factor A. Produced in mammalian cells with native-like glycosylation.
Highlights
|
| Reactividad de especies | Human |
| Aplicaciones | ELISA, Bioactivity: FCM, Functional assay, Research in vivo |
| Especie huésped | Human |
| Clonalidad | Monoclonal |
| Isotipo | IgG |
| ID de clon | DRL_BZ |
| Objetivo | L-VEGF, N-VEGF, VEGF, VEGFA, VPF, Vascular endothelial growth factor A, long form, Vascular permeability factor |
| Nivel de endotoxinas | < 10 EU/mg |
| Pureza | >95% as determined by SDS-PAGE. |
| Purificación | Protein A/G purified from cell culture supernatant. |
| Número de acceso | P15692 |
| Forma | Liquid |
| Buffer de almacenamiento | 0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote. |
| Estabilidad y almacenamiento | Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt. |
| Nombres alternativos | DRL_BZ |
| Fondo | Vascular endothelial growth factor A, long form (VEGFA) is a ~43 kDa protein. Participates in the induction of key genes involved in the response to hypoxia and in the induction of angiogenesis such as HIF1A. Involved in protecting cells from hypoxia-mediated cell death. VEGFA is the therapeutic target of bevacizumab (Avastin). 1. Katsman, M. et al. (2022) Cells 11. PMID: 35455969 |
| Nota | For research use only. Not suitable for clinical or therapeutic use. |

SDS-PAGE for Research Grade Anti-Human VEGFA (DRL_BZ)




Contáctenos para cotizaciones personalizadas, solicitudes en masa y cualquier otro problema.
Correo: [email protected]


+86-027-65523339
Edificio C, No. 666, Calle Shendunsi, Wuhan, 430206, China
中文
English
한국어
日本語
Español
Français
Русский